Literature DB >> 30339381

Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers.

Julien P N Papillon, Katsumasa Nakajima, Christopher D Adair, Jonathan Hempel, Andriana O Jouk, Rajeshri G Karki, Simon Mathieu, Henrik Möbitz1, Rukundo Ntaganda, Troy Smith, Michael Visser, Susan E Hill, Felipe Kellermann Hurtado, Gregg Chenail, Hyo-Eun C Bhang, Anka Bric, Kay Xiang, Geoffrey Bushold, Tamara Gilbert, Anthony Vattay, Julie Dooley, Emily A Costa, Isabel Park, Ailing Li, David Farley, Eugen Lounkine, Q Kimberley Yue, Xiaoling Xie, Xiaoping Zhu, Raviraj Kulathila, Daniel King, Tiancen Hu, Katarina Vulic, John Cantwell2, Catherine Luu2, Zainab Jagani.   

Abstract

SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2), also known as Brahma homologue (BRM), is a Snf2-family DNA-dependent ATPase. BRM and its close homologue Brahma-related gene 1 (BRG1), also known as SMARCA4, are mutually exclusive ATPases of the large ATP-dependent SWI/SNF chromatin-remodeling complexes involved in transcriptional regulation of gene expression. No small molecules have been reported that modulate SWI/SNF chromatin-remodeling activity via inhibition of its ATPase activity, an important goal given the well-established dependence of BRG1-deficient cancers on BRM. Here, we describe allosteric dual BRM and BRG1 inhibitors that downregulate BRM-dependent gene expression and show antiproliferative activity in a BRG1-mutant-lung-tumor xenograft model upon oral administration. These compounds represent useful tools for understanding the functions of BRM in BRG1-loss-of-function settings and should enable probing the role of SWI/SNF functions more broadly in different cancer contexts and those of other diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30339381     DOI: 10.1021/acs.jmedchem.8b01318

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  30 in total

1.  Acute BAF perturbation causes immediate changes in chromatin accessibility.

Authors:  Sandra Schick; Sarah Grosche; Katharina Eva Kohl; Danica Drpic; Martin G Jaeger; Nara C Marella; Hana Imrichova; Jung-Ming G Lin; Gerald Hofstätter; Michael Schuster; André F Rendeiro; Anna Koren; Mark Petronczki; Christoph Bock; André C Müller; Georg E Winter; Stefan Kubicek
Journal:  Nat Genet       Date:  2021-02-08       Impact factor: 38.330

2.  Chemical Inhibitors of a Selective SWI/SNF Function Synergize with ATR Inhibition in Cancer Cell Killing.

Authors:  Emma J Chory; Jacob G Kirkland; Chiung-Ying Chang; Vincent D D'Andrea; Sai Gourisankar; Emily C Dykhuizen; Gerald R Crabtree
Journal:  ACS Chem Biol       Date:  2020-05-27       Impact factor: 5.100

3.  The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer.

Authors:  Chai Bandlamudi; Jessica A Lavery; Joseph Montecalvo; Azadeh Namakydoust; Natasha Rekhtman; Gregory J Riely; Adam J Schoenfeld; Hira Rizvi; Jacklynn Egger; Carla P Concepcion; Sonal Paul; Maria E Arcila; Yahya Daneshbod; Jason Chang; Jennifer L Sauter; Amanda Beras; Marc Ladanyi; Tyler Jacks; Charles M Rudin; Barry S Taylor; Mark T A Donoghue; Glenn Heller; Matthew D Hellmann
Journal:  Clin Cancer Res       Date:  2020-07-24       Impact factor: 12.531

Review 4.  Pharmacological Modulation of Transcriptional Coregulators in Cancer.

Authors:  Timothy R Bishop; Yuxiang Zhang; Michael A Erb
Journal:  Trends Pharmacol Sci       Date:  2019-05-08       Impact factor: 14.819

5.  Mammalian SWI/SNF continuously restores local accessibility to chromatin.

Authors:  Mario Iurlaro; Michael B Stadler; Francesca Masoni; Zainab Jagani; Giorgio G Galli; Dirk Schübeler
Journal:  Nat Genet       Date:  2021-02-08       Impact factor: 38.330

6.  BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency.

Authors:  Manav Gupta; Carla P Concepcion; Caroline G Fahey; Hasmik Keshishian; Arjun Bhutkar; Christine F Brainson; Francisco J Sanchez-Rivera; Patrizia Pessina; Jonathan Y Kim; Antoine Simoneau; Margherita Paschini; Mary C Beytagh; Caroline R Stanclift; Monica Schenone; D R Mani; Chendi Li; Audris Oh; Fei Li; Hai Hu; Angeliki Karatza; Roderick T Bronson; Alice T Shaw; Aaron N Hata; Kwok-Kin Wong; Lee Zou; Steven A Carr; Tyler Jacks; Carla F Kim
Journal:  Cancer Res       Date:  2020-07-20       Impact factor: 12.701

Review 7.  Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy.

Authors:  Marek Wanior; Andreas Krämer; Stefan Knapp; Andreas C Joerger
Journal:  Oncogene       Date:  2021-05-03       Impact factor: 8.756

Review 8.  Using Chemical Epigenetics to Target Cancer.

Authors:  Virangika K Wimalasena; Tingjian Wang; Logan H Sigua; Adam D Durbin; Jun Qi
Journal:  Mol Cell       Date:  2020-05-13       Impact factor: 17.970

9.  Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung.

Authors:  Sai Ma; Lindsay M LaFave; Arjun Bhutkar; Carla P Concepcion; Manyuan Liu; Lydia P DeAngelo; Jonathan Y Kim; Isabella Del Priore; Adam J Schoenfeld; Manon Miller; Vinay K Kartha; Peter M K Westcott; Francisco J Sánchez-Rivera; Kevin Meli; Manav Gupta; Roderick T Bronson; Gregory J Riely; Natasha Rekhtman; Charles M Rudin; Carla F Kim; Aviv Regev; Jason D Buenrostro; Tyler Jacks
Journal:  Cancer Discov       Date:  2021-09-24       Impact factor: 38.272

Review 10.  The SWI/SNF complex in cancer - biology, biomarkers and therapy.

Authors:  Priya Mittal; Charles W M Roberts
Journal:  Nat Rev Clin Oncol       Date:  2020-04-17       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.